Article

August 7, 2012

Mark Zitter, MBA, Discusses Oncology Pathways

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.

Related Videos

Jonathan Eisengart, MD

Chelsee Jensen, PharmD, BCPS.

Jonathan Eisengart, MD

Sarah Anderson, oncology strategy lead director, Novotech

Jonathan Eisengart

Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center

Jonathan Eisengart

Tiago Biachi, MD, PhD

Irina Dralyuk

Related Content

Oncology Research | Image credit: iStock

January 30th 2025

Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Kirollos Hanna, PharmD

January 29th 2025

Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

January 23rd 2025

Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees

Brooke McCormick Ju-Chen Hu, PhD

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

FDA Approval | Image credit: wladimir1804 - stock.adobe.com

January 29th 2025

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

FDA approval | image credit: Aquir - stock.adobe.com

January 28th 2025

FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

Related Content

Oncology Research | Image credit: iStock

January 30th 2025

Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Kirollos Hanna, PharmD

January 29th 2025

Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

January 23rd 2025

Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees

Brooke McCormick Ju-Chen Hu, PhD

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

FDA Approval | Image credit: wladimir1804 - stock.adobe.com

January 29th 2025

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

FDA approval | image credit: Aquir - stock.adobe.com

January 28th 2025

FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions